Stay updated on Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.4.3, replacing the previous Revision: v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-12T02:16:18.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    A new site Revision: v3.4.2 appears, and the previous government funding notice (and Revision: v3.4.1) has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T12:33:22.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    A site-wide notice about government funding lapse and NIH Clinical Center status was added, and the system revision updated to v3.4.1 (replacing v3.4.0).
    Difference
    0.4%
    Check dated 2026-02-04T06:54:16.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Added access to the Study Protocol and Statistical Analysis Plan PDF, IPD sharing information and URLs, and Merck-related resources, and introduced glossary visibility with updated metadata.
    Difference
    51%
    Check dated 2026-01-28T04:48:01.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Minor update: Revision: v3.3.4 was added and Revision: v3.3.3 was removed on the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T01:56:07.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    Footer updates show Revision: v3.3.3 and removal of the HHS Vulnerability Disclosure; these are minor site maintenance changes and do not affect the study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-23T10:25:48.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page.